Jasper Therapeutics Inc Stock Price, News & Analysis

Jasper Therapeutics (NASDAQ: JSPR) will host a KOL webinar on April 28, 2022, at 1:00 p.m. ET, focusing on advancements in hematopoietic stem cell therapies. Key opinion leaders, Dr. Lori Muffly and Dr. David Sallman, will discuss the current challenges in stem cell transplant conditioning and myelodysplastic syndromes (MDS) treatment. The presentation will highlight JSP191, a targeted monoclonal antibody in clinical development, showcasing its potential in addressing transplant conditioning limitations for lower-risk MDS patients. A live Q&A session will follow the presentations.

Jasper Therapeutics (NASDAQ: JSPR) announced that updated data on JSP191, a monoclonal antibody, has been accepted for presentation at the 2022 Clinical Immunology Society Annual Meeting in Charlotte, NC, from March 31 to April 3. The study shows JSP191's potential to improve donor cell engraftment and immune reconstitution in severe combined immunodeficiency (SCID) patients who have failed previous transplants. CEO Ronald Martell emphasized the importance of this data for the SCID community, highlighting their commitment to delivering targeted therapies for these patients.

Jasper Therapeutics (Nasdaq: JSPR) announced on March 21, 2022, the granting of an option for 1,704,328 shares of common stock to new CEO Ronald Martell. This option, part of the 2022 Inducement Equity Incentive Plan, carries an exercise price of $3.54 per share and will vest over four years. Jasper focuses on hematopoietic cell transplantation therapies, notably advancing its anti-CD117 monoclonal antibody, JSP191, aimed at improving transplantation safety and effectiveness. The company remains committed to developing innovative therapies for life-threatening conditions.

Jasper Therapeutics (NASDAQ: JSPR) announced management changes effective March 21, 2022, including Jeet Mahal as Chief Operating Officer and Wendy Pang, M.D., Ph.D., as Senior Vice President of Research and Translational Medicine. A search for a Chief Medical Officer is underway. These moves aim to streamline operations and enhance clinical development for JSP191, a monoclonal antibody in clinical trials for AML/MDS. CEO Ronald Martell highlighted the need for a stronger organizational structure to support upcoming pivotal trials and pipeline execution.

Jasper Therapeutics (NASDAQ: JSPR) reported its fiscal year 2021 results, highlighting significant advancements in its JSP191 therapy for hematopoietic stem cell transplants. In a Phase 1b study, JSP191 demonstrated a safety record with 100% engraftment and MRD clearance in patients. The company plans to initiate pivotal studies for MDS/AML and a second-line therapeutic study in 2022. Financially, it ended 2021 with $84.7 million in cash, sufficient to fund operations into early 2023. R&D expenses increased to $25.4 million, while net loss decreased slightly to $30.6 million.

Jasper Therapeutics, Inc. (NASDAQ: JSPR) announced its participation in the 32nd Annual Oppenheimer Healthcare Investor Conference, taking place virtually from March 15-17, 2022. Ronald Martell, CEO, will present on March 16 at 1:20 PM ET, with a live webcast available for viewing. Jasper is focused on developing innovative hematopoietic cell transplant therapies, including JSP191, a monoclonal antibody aimed at improving transplant safety and efficacy. The company also advances a preclinical mRNA engineered hematopoietic stem cell platform, designed to enhance treatment options for patients with serious conditions.

Jasper Therapeutics announces Ronald Martell as the new CEO, effective March 15, 2022. Martell, with a strong background in biopharmaceuticals, aims to lead the company through its next growth phase. He emphasized the potential of Jasper's JSP191 and mRNA engineered stem cell programs, citing promising Phase 1b clinical data showing 100% engraftment success in patients with MDS/AML. Jasper's programs target safer stem cell transplants to treat various diseases. The company has a solid financial foundation and is focusing on advancing its clinical pipeline.

Jasper Therapeutics announced promising preliminary findings from a Phase 1b study of JSP191 in older patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). All 17 subjects in the trial achieved successful engraftment with neutrophil recovery, and 12 of 15 patients with measurable residual disease cleared their conditions. JSP191 demonstrated a favorable safety profile, with no severe adverse events reported. These results, to be presented at the 2022 TCT meeting, signal potential for JSP191 as a new conditioning agent in hematopoietic stem cell transplants.

Jasper Therapeutics (NASDAQ: JSPR) announced promising data on JSP191, presented at the 2021 American Society of Hematology Annual Meeting. The study showed JSP191 to be well tolerated, with no treatment-related adverse events reported among patients aged 3 months to 38 years. A total of six out of nine patients achieved hematopoietic stem cell (HSC) engraftment and demonstrated clinical improvement. The ongoing study is evaluating the 0.6 mg/kg dose as a potential recommended Phase 2 dose. JSP191 aims to enhance the safety and efficacy of hematopoietic cell transplants for severe combined immunodeficiency (SCID).